OLON ANNOUNCES A STRATEGIC EXPANSION TO PRODUCE PROTEINS WITH AN ADVANCED AND SUSTAINABLE APPROACH

PAOLO TUBERTINI, CEO, COMMENTS “WE WILL BE ABLE TO SUPPORT INNOVATIVE BIOTECH COMPANIES TO ACCELERATE THE DEVELOPMENT OF NEW PRODUCTS, COMBINING MORE ADVANCED AND SUSTAINABLE MANUFACTURING” 

Milano, September 6th, 2021 – Olon is delighted to announce a major expansion of its Italian site located in Settimo Torinese, which is a historical asset of the global manufacturing network of the Group and moreover represents a centre of excellence for biotechnological manufacturing. The expansion is a key milestone for the site and a cornerstone of the Company strategy that is fostering the development of its biotechnological platform, both in terms of expertise and production capacity. 

Olon will build and operate the new area with advanced technologies that, relying on the deep expertise in biomanufacturing, will produce proteins following innovative and highly sustainable processes. Microbial fermentation is one of the most eco-friendly and sustainable technology. 

The expansion will allow Olon to increase its capacity to accommodate new and existing clients’ needs, it fits in the strategy of expanding the CDMO services in different market segments. “We are significatively investing in our fermentation capacity following market trends that show an increased demand for microbial bio-manufactured compounds. Offering our expertise in CDMO services and biotechnological platforms as well, we are able to support innovative biotech companies to accelerate the development of new products, combining it with a more sustainable manufacturing approach” explains Paolo Tubertini, CEO at Olon Group. “We are fully committed to understand and meet our customers’ needs, as we continuously seek to provide new capacity and services.”

Thanks to this investment the site of Settimo Torinese will offer the production capacity for the significant volumes needed to sustain the launch of new products.

Relying on an experience gained over more than 50 years, Olon Biotechnology Centres represents one of the most extensive know-how of microbial fermentation in Europe. Expertise and competence are combined with great flexibility at different levels related to the knowledge of various microorganisms and fermentation processes. Flexibility also reflects in the isolation and purification steps because they can rely on 20 different downstream plants. Furthermore, Biotechnology Centres can count on outstanding internal engineering capabilities and expertise. The global footprint led Olon to be one of the leaders in producing via microbial fermentation for third parties globally, thanks to our size and the overall production capacity – 4,500m3.

With a 2020’s Turnover of 530 Mio$, OLON supplies 34 Chemical Intermediates and more than 295 APIs for the Generic market. 

Thanks to all the 2.200 employees, and to highly qualified R&D team – more than 200 people – OLON can offer complete integrated packages and services to support the full development of APIs based on strong knowledge in both Chemical and Biological processes, all of them under a full cGMP and regulatory coverage – holder of about 160 active US DMFs and 79 granted CoS. 

Always considering human safety and environmental security, OLON handles different and not-common manufacturing process technologies, such as Fluorination, Carbonylation, and Fermentation – combined with chemical synthesis to produce APIs for the majority, proteins, high-value small molecules & microorganisms (application in pharma), food, feed, and other bio-industrial markets.

Headquartered in Rodano (Milan, Italy), OLON has 11 manufacturing facilities – 8 located in Italy, 1 in Spain, 1 in USA and 1 in India, designed in compliance with the strictest international requirements, and 3 branch offices in Hamburg (Germany), Florham Park NJ (USA) and Shanghai (China). 

The manufacturing sites are regularly inspected by the most important national and international Authorities, and regularly audited by our partners and customers. The facilities are FDA-inspected and self-identified under GDUFA. 

Besides pharmaceutical certifications, OLON complies with ISO standards (14001), has dedicated areas for food-grade manufacturing and complies with Kosher, Halal and within 2018-Q3 also with FSSC 22.000.

To be highlighted OLON’s growing cooperation with Universities: University of Milan (Italy), Milan Politecnico (Italy), University of Pavia (Italy), University of Murcia (Spain), and PROMIDIS (Milan University spin-off).

www.olonspa.com / cdmo@olonspa.it

Media contact

Sabrina Spina

sspina@olonspa.it – mobile 338.6674289

OLON PRESENTS ITS NEW SUSTAINABILITY MANIFESTO

Olon is proud to present its Sustainability Manifesto 2021, published today on our corporate media. The new Manifesto represents a transparent report of the commitment and results that the Group is pursuing globally, in each country it operates, and consistently with its strategy.

Olon has set very ambitious global targets of sustainability regarding waste and consumption of natural resources and energy as well. Starting from today, based on the milestone of a new Manifesto, the Group states its commitment to publishing sustainability on an annual basis.

Sustainability is an essential part of Olon’s mission, which the company is pursuing with determination and perseverance, combined with an ambitious vision for the future: becoming a global leader in the production of APIs from an ethical and environmental perspective.

Today the company embraces a new dimension of sustainability, that integrates respect for the environment with caring people. Olon promotes and supports a new industrial model that sets far-sighted goals while never forgetting how precious people and natural resources are, which need to be protected. Playing the role of market leader also carries a social weight because it means performing a driving and motivational task.

OLON Sustainability Manifesto 2021

Olon atteding CPHI North America

Meet us a the forthcoming CPHI North America. We are excited to announce that, after the thought period, CPHI North America is coming back as a hybrid event digital and in person.

One of the major events of the industry will take place from July 26 to August 6, in virtual, and from August 10 to 12 in person, in Philadelphia.

Olon will officially attend with a virtual exhibition, visit our complete company profile here About Olon Spa.

Rolling out our products and services, team members, latest corporate news.

We’ll be present at the event in Philadelphia with our marketing team.

OLON ANNOUNCES A NEW HIGHLY POTENT API EXPANSION IN ITS RODANO SITE

Milan, 24th June 2021 – The Group’s new results have been announced by Olon, global leader of APIs production, upon the closure of the 2020 financial statements: the company confirms its trend of organic growth, the success of the integration process of the industrial and research and development activities of the numerous sites acquired in recent years, achieving its absolute historical record in terms of revenues, technical and R&D investments.

Olon closed its books with numbers that reflect a gradual and constant growth over the last five years: 65 million in strategic investments over 2021, focusing to boost most advanced technology platforms and expanding production capacity as well. The forward-looking strategy of the Italian Group focuses on production of highly potent active principles.   

In the context of this exceptional international growth, the Rodano (Milan) site has been subject to major investments which have allowed the plant to significantly increase its production capacity and to raise its process quality standards, along with its environmental sustainability and the safety of its workers. The plant has extensive experience and capabilities in the development and manufacturing of highly potent APIs from clinical to commercial scale. In 2021 alone, the Rodano site received investments of 13 million to bolster it on several fronts.

Olon is pleased to announce the completion of a new highly potent API large scale production line, already available for customers. A new, highly automated production line, multi-purpose, and high-containment, suitable for the synthesis of highly active ingredients.

Rodano site, that relies on one of the most extensive expertise in handling highly potent pharmaceutical principles at global level, has raised the level of containment up to the actual standards and very large scale putting in place a set of primary and secondary containment designed to avoid the active substances diffusion in the working environment.

The line significantly strengthens the synthesis, finishing and drying section, to manage acid-based reactions and it can produce batches up to the significant quantity of 250 kg, with a necessary containment band of OEB5, for either highly active or highly toxic products (OEL 0,1-1 micrograms/m3).

“Our new production line in Milan is part of a development capacity expansion to address the strong market demand and furtherly reinforce our historical expertise in handling highly potent pharmaceutical ingredients. This additional capacity benefits customers by expediting the onboarding of new projects”comments Paolo Tubertini, Group Chief Executive Officer

Finally, the group, in line with its vision, has invested major resources into workplace safety, protection of individuals and protection of the environment. “Our aim is to continue to grow. We play a leading role as an Italian company but also as representatives of an industry that is crucial to public health and to the drug supply chain. We hope to pave the way to bring back to Europe the production of active ingredients, which represent the heart of the drug” concludes Roberta Pizzocaro, President of Olon Group.

Paolo Tubertini, CEO of Olon, interviewed by Global Business Report about Olon case history, strategy, investments, future

Olon tracks its roots to 1907, but it was 10 years ago that the company was integrated as Olon Spa. Could you share the latest developments?

When I joined Olon at the beginning of the 2000s, Olon’s primary vision was to become a leader in the production of APIs and intermediates. Once we began to see this vision realized, we started looking at the bigger picture – our role in society and the company’s long-term future. This introspection led to a re-established mission for the company, redefining our role around two pillars: challenging and innovating the way we deliver science, and improving the lives of people. Today, we are one of the largest European suppliers of APIs for both the generic and CDMO markets. We are very active in high potency drugs such as cytotoxic substances, as well as antineoplastic compounds, immunosuppressive agents, hormones, antibiotics, and controlled substances. We have 11 manufacturing plants, eight of which are in Italy, one in Spain, one in the US, and one in India.

Olon made a couple of acquisitions in recent years, expanding its footprint in the US and India as well as in biotech technologies. Could you share the strategy behind these acquisitions?

Over the last few years, we have been investing heavily in both organic and inorganic growth. We acquired Infa Group back in 2016, doubling our generics line. Later in 2017, we acquired the Olon Ricerca Biosciences, a centre fully dedicated to R&D that is based in Ohio. It offers world-class contract research and manufacturing services and a broad array of capabilities with an integrated approach to chemical development. In 2018, Olon acquired Italy-based Capua BioServices, a CDMO company highly specialised in microbial manufacturing. Capua BioServices, based in Italy, expanded our capabilities in this technology and allowed us to take our offer to the food industry. Finally, we made a strategic acquisition in India to expand our integrated portfolio, services and technology platforms.

How does Olon leverage the dual model of API and CDMO supplier?

Traditionally, the pharma industry used to separate the API and CDMO businesses, but I believe there is a case for innovating around an integrated model and leveraging on the synergies created. For instance, we can translate our generics expertise in regulatory matters into the CDMO business. With 350 compounds sold worldwide, Olon has a deep knowledge of global regulations, which we want to inoculate across the structure of the organization, adding value to the CDMO business.

Reversely, we found an opportunity to borrow from the strengths of the CDMO business when it comes to equipment usage. CDMOs are strictly engaged with order agreements from a single customer, which often leads to the under-utilization of an asset. At Olon, we fill the remaining capacity with generic compounds, based on stock levels. In this way, we optimize asset use without compromising service availability to customers. Finally, Olon not only take the partner through the entire journey but is also able to share the responsibility of a product’s performance as part of a contract with transparency. In conclusion, we have the capability to play a crucial role in reaching the final success of the development process.

What do you think is Italy’s competitive advantage as an outsourcing destination for CMDO?

Italy is a leading producer in Europe and the pharma sector accounts for around €33 billion per year, a commensurate figure for a country of our size. Italy offers a rich ecosystem of universities, services, machinery producers, research technicians, analytical labs, all in proximity.

How has Olon contributed to the fight against the pandemic?

We are working as part of five different programs for the development of antiviral drugs. Since the pandemic, we have prioritized imminent health needs and we were able to coordinate with our partners to boost production for some product lines at the detriment of others: When one partner interested in an innovative antiviral API drugs, for instance, asked us to ramp up production at our Rodano site, our other customers showed tremendous understanding and supported us, knowing they can trust us for recouping the volumes when the emergency had passed. Meanwhile, they relied on stock supplies. The industry’s synchronic mobilization is an example of global collaboration and solidarity.

What is Olon’s current innovation focus?

At Olon, we first look at innovation in terms of innovating the way we make things – our production processes, technologies and market strategies. Within this wider program of innovation, we also see innovation as investing in new technologies, such as flow chemistry, enzymatic production and high potency drugs – a landmark space for Olon, where we have been present for 50 years. Personalized and precision medicine will require smaller drugs and therefore, smaller reactors, which will inadvertently increase prices, so we keep abreast of these developments. In 2021, we foresee a total capital investment of €65 million, which is roughly 12% of our sales.

Olon set out to reduce CO2, GHG, and water consumption by 50% between 2015 and 2025. Could you finalize with a few words on the company’s understanding of sustainable growth?

Because we set these targets early on, we are on track to meet them in the next few years. I believe it is important to let our stakeholders know of our commitments to the community and climate. We are constantly committed to reduce the impact on the environment where we operate and to promote a more sustainable API manufacturing approach. We have very aspiring targets to reduce consumption of water and energy, to decrease wastes and carbon dioxide emissions.

link: Global Business Reports – Paolo Tubertini (gbreports.com)

Francesco Pizzocaro is the new Knight of Labor of Chemistry and Pharmaceutical Industry.

It is a very special day for Olon Group. Francesco Pizzocaro, President of P&R, the Holding Company which Olon belongs to,has received the honour of Cavaliere del Lavoro by the President of Italian Republic Sergio Mattarella with an official ceremony hosted in Quirinale. We express our proud for this honour together with our biggest congratulations to him.

The Knighthood of the Republic is the highest honour established by the President of Republic to recognise the value of those Italian enterprises that have produced significative results in terms of work, social commitment, innovation, internationalization.

About the appointment as Cavaliere del Lavoro, Francesco Pizzocaro commented: “I am sincerely honored of having received this recognition that, as Italian citizen, I have always looked at one of the most coveted honours for professional life. I sincerely thank the President of Republic, those Italian Institution who awarded me with this prestigious title, all the collaborators with whom I have worked along my professional life. It is also thanks to them that today I can experience this beautiful and important event”.

Meet the Champions

Today ItalyPost Think Tank and Corriere Della Sera Economia promote a roundtable between Presidents of Italian Companies that are driving our economic and social growth, giving a key contribution to employment and development. As major player and global leader of API industry, we will be part of the discussion to share our vision and experience. Our President Roberta Pizzocaro will join the discussion on “Sustainability as a new Competitive Factor”, sharing actions, ideas, and models by which OLON is pursuing sustainability. OLON is constantly committed to reduce the impact on the environment and to promote a more sustainable API manufacturing approach. We have also very challenging targets to reduce consumption of water and energy, to decrease wastes and carbon dioxide emission. Roberta Pizzocaro will share OLON vision on sustainability overall.

Olon SpA 🏆 DWF International Awards

Olon Group has been awarded for the performance achieved in 2020, with a prestigious prize received by The British Chamber of Commerce during the latest BCCI Business Excellence Awards. Olon has been awarded for the international growth and the company global development.  

Paolo Tubertini, Managing Director, and Alfio Mason, CFO, received the recognition during the award ceremony. Together with Olon Group, a few companies have been awarded by BCCI as business excellence, a pool of leading companies from other industries with globally trusted brands.

“We are very proud of this Award” stated Paolo Tubertini, Olon Managing Director “Our successful entrepreneurial history let us turn into a worldwide leader, with an Italian headquarter and a global footprint. We will keep on investing and growing”.

“I give thanks to Tom Noad, President of British Chamber of Commerce, and to Jill Morris CMG, HM Ambassador. A special thanks to all the colleagues who gave contribution to this significant result” said Alfio Mason, Olon CFO.

Look at the video on Youtube to see the Ceremony moment: https://lnkd.in/eW9vsvJ

Olon commitment for World Health Day

Today we celebrate #WorldHealthDay. Olon contributes to fight against global pandemics. We play a key role for the access to therapies, providing active principles that treat major global diseases such as tuberculosis, sickle cell disease, leprosy. This is key for global issues and it is a focus for Olon. Our mission is to challenge and innovate the way to deliver science, to improve the health of all human beings. For #WorldHealthDay we remind how relevant it is to believe in science as a solution to promote health and to improve the quality of #life. We are committed, as key player of the pharmaceutical supply chain, to be innovative every day, #researching and #developing.

Stay safe: believe in science!

Industria Felix Prize 2021

OLON has been awarded by the Prize Industria Felix 2021 to be one the best companies for its international vocation, performance of management and financial reliability.

IndustriaFelix is one of the most influencing events about economy and finance among Italian press. The Prize is a full recognition creativity, fervour and determination to those who demonstrate the capacity to build an enterprise producing significative results in terms of social wealth and economic progress.

The companies have been selected by a skilled Scientific Committee, after a journalist survey that analysed 142 thousand financial reports. Among these, the Commission has awarded the 43 most competitive corporations, based in Lombardia, considering management performance, financial reliability, sustainability. These corporations, including Olon, have received The Financial Management Honour of the Prize Industria Felix.

The mission of Industria Felix is promoting a network between valuable companies to promote the image of Italian competitiveness.

“We are proud to be awarded by this prestigious Prize that proves our key role, not only in the chemistry industry but also in the social and economic fabric of Lombardia Region” has commented Drssa Roberta Pizzocaro, President of Olon “Olon contributes to the competitiveness of Lombardia Region considering that our performance let us double our size over the last few years”.

X